0
Clinical Trial ? AI-assigned paper type based on the abstract. Classification may not be perfect — flag errors using the feedback button. Tier 1 ? Systematic review or meta-analysis. Synthesizes findings across many studies. Strongest evidence. Environmental Sources Human Health Effects Remediation Sign in to save

Novel Therapeutic Strategies in Alzheimer’s Disease: Pitfalls and Challenges of Anti-Amyloid Therapies and Beyond

Journal of Clinical Medicine 2024 22 citations ? Citation count from OpenAlex, updated daily. May differ slightly from the publisher's own count. Score: 75 ? 0–100 AI score estimating relevance to the microplastics field. Papers below 30 are filtered from public browse.
Giacomo Tondo, Fabiola De Marchi, Francesca Bonardi, Federico Menegon, Gaia Verrini, Davide Aprile, Matteo Anselmi, Letizia Mazzini, Cristoforo Comi

Summary

This review examines why clinical trials targeting amyloid-beta for Alzheimer's disease have largely failed, and explores emerging alternatives including tau-targeted therapies, neuroinflammation modulation, and gene therapy. The study is not directly related to microplastic research.

Models

Alzheimer's disease (AD) causes a significant challenge to global healthcare systems, with limited effective treatments available. This review examines the landscape of novel therapeutic strategies for AD, focusing on the shortcomings of traditional therapies against amyloid-beta (Aβ) and exploring emerging alternatives. Despite decades of research emphasizing the role of Aβ accumulation in AD pathogenesis, clinical trials targeting Aβ have obtained disappointing results, highlighting the complexity of AD pathophysiology and the need for investigating other therapeutic approaches. In this manuscript, we first discuss the challenges associated with anti-Aβ therapies, including limited efficacy and potential adverse effects, underscoring the necessity of exploring alternative mechanisms and targets. Thereafter, we review promising non-Aβ-based strategies, such as tau-targeted therapies, neuroinflammation modulation, and gene and stem cell therapy. These approaches offer new avenues for AD treatment by addressing additional pathological hallmarks and downstream effects beyond Aβ deposition.

Share this paper

Discussion

Log in to join the discussion

No comments yet. Be the first to share your thoughts.